Reviewed by Michael Gill, B. Sc.
4 Alli Clinical Trials Near Me
Top Cities for Alli Clinical Trials
Image of Loma Linda in California.
Loma Linda
1Active Trials
Novo Nordisk Investigational SiteTop Active Site
Image of Cleveland in Ohio.
Cleveland
1Active Trials
Cleveland ClinicTop Active Site
Alli Clinical Trials by Phase of Trial
Phase 2 Alli Clinical Trials
2Active Alli Clinical Trials
2Number of Unique Treatments
1Number of Active Locations
Most Recent Alli Clinical Trials
Clinical Trial
Began Recruiting Date
Phase

What Are Alli Clinical Trials?

Alli is a brand name variant of a drug named Orlistat that blocks the absorption of fat from food, thereby acting as an aid to weight loss. It is considered effective when use is combined with a low-fat diet and a healthy fitness routine.

Due to its tendency to reduce the ability of the body to metabolize fat from food, Alli is being studied for its ability to reduce triglyceride levels, as a treatment for obesity, type 2 diabetes mellitus, and obstructive sleep apnea. Because these conditions have a great deal of causal and symptomatic overlap, it is believed that the effects researchers are looking for have a high probability of manifesting in clinical trials.

Why Is Alli Being Studied In Clinical Trials?

Alli is one of the most popular prescription weight loss drugs ever made, and its success has made it possible for doctors, clinicians, and researchers to gather an enormous amount of data on its use, effects, and safety. Overall, the currently ongoing studies have demonstrated very high levels of safety, and moderate levels of effectiveness.

While the effectiveness of Alli in use as a treatment for type 2 diabetes Mellitus, has been high, success in reducing high triglyceride levels and obstructive sleep apnea has been moderate at best. However, because of the strong physiological connection between these conditions and obesity, and because Alli is known to be an effective treatment for obesity, the researchers behind these studies remain hopeful.

How Does Alli Treatment Work?

Alli is taken with liquid either while eating or after a meal. It is best to take it with food or within one hour after eating. An hour after eating is considered the latest point at which it should still be effective in blocking the absorption of fats.

Alli works by blocking the action of lipases. These are enzymes that attach to and carry fat through the tissues of the digestive tract into the bloodstream, thereby removing the mechanism by which fat is absorbed.

Alli is meant to be taken three times a day at most, or once with each meal. The greatest concern with this drug is that users may consume more fat than they would normally consume, and thereby overwhelm the ability of the Alli to work. Aside from this, safety concerns are considered moderate to low.

What Are Some of the Breakthrough Clinical Trials Involving Alli?

The following studies are only a sample of the dozens of promising clinical trials that have been and are being conducted concerning the weight loss drug, Alli.

First clinical studies with Alli: a short review

Alli Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Multifactorial Approach Associated With Alli for 4 Years Weight Loss Maintenance in Obese Adults

Study of Fat Malabsorption by Lipiblock Versus Alli

Alli Induced Modulation on the Fatty Acid Composition in Obese Females

Who Are The Key Opinion Leaders On Alli Clinical Trial Research?

Sanjai Sinha, MD

M L Drent

E A van der Veen

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 20th, 2021

Last Reviewed: October 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Patni N, Quittner C, Garg A. Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2403-2407. doi: 10.1210/jc.2018-00369. https://pubmed.ncbi.nlm.nih.gov/29659879